Frontlight ResearchEarly access
Lung cancer trials in South Korea
170 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Where
- Cheongju-si, Goyang-si, Jinju, Seongnam, Seoul, Suwon
- Age
- 18 years and over
- People
- 686 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- Busan, Deagu, Junggu, Seoul
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00 - Phase 2Taking peopleStudy of PF-07248144 in Advanced or Metastatic Solid Tumors
- Where
- Daegu, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 320 worldwide
- Run by
- Pfizer
See details and how to joinNCT04606446 - Phase 2Taking peopleNeoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Where
- Busan, Chungcheongbuk-do, Seongnam-si, Seoul, Suwon
- Age
- 18 years to 95 years
- People
- 630 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05061550 · EU 2023-508852-21-00 - Phase 3Taking peopleStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Where
- Changwon-Si, Gwangju, Seongbuk-Gu, Seongnam, Seoul, Suwon, Ulsan
- Age
- 18 years and over
- People
- 695 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06801834 - Phase 1/2Taking peopleGI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- Where
- Daejeon, Seoul, Suwon
- Age
- 18 years and over
- People
- 317 worldwide
- Run by
- GI Innovation, Inc.
See details and how to joinNCT04977453 - Phase 1/2Active, not recruitingStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Where
- Goyang-si, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 616 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06162221 · EU 2025-521147-21-00 - Phase 1/2Taking peopleA Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- Where
- Gyeonggi-do, Seoul
- Age
- 18 years and over
- People
- 293 worldwide
- Run by
- Frontier Medicines Corporation
See details and how to joinNCT06244771 - Phase 1/2Taking peopleA Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
- Where
- Seoul
- Age
- 18 years and over
- People
- 80 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07564401 - No phaseTaking peopleProspective Observational Study of Baseline Tumor Genomic Profiling and Circulating Tumor DNA in Neoadjuvant Chemoimmunotherapy for Stage IB-III Non-Small Cell Lung Cancer
- Where
- Seoul
- Age
- 19 years and over
- People
- 300
- Run by
- Yonsei University
See details and how to joinNCT06907160 - Phase 2Taking peopleA Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
- Where
- Cheongju-si, Namdong-gu, Seongnam-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 278 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07098338 · EU 2025-524843-11-00 - Phase 3Taking peopleSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Where
- Cheongju-si, Goyang-si, Incheon, Jinju, Seoul, Suwon
- Age
- 18 years and over
- People
- 621 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06712355 · EU 2024-515765-34-00 - Phase 1Taking peopleA Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
- Where
- Seoul
- Age
- 18 years and over
- People
- 110 worldwide
- Run by
- EpiBiologics
See details and how to joinNCT07462377 - Phase 1/2Taking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Seoul
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - Phase 3Not yet taking people in South KoreaBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
- Where
- Seoul, Soeul
- Age
- 18 years to 100 years
- People
- 96 worldwide
- Run by
- InSightec
See details and how to joinNCT05317858 - Phase 3Taking peopleA Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- Where
- Cheongju-si, Daegu, Goyang-si, Hwasun-gun, Incheon, Jeonju, Jinju, Pusan, Seongnam-si, Seoul, Suwon, Yangsan
- Age
- 18 years and over
- People
- 360 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00 - Phase 2Not yet taking people in South KoreaA Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
- Where
- Seoul
- Age
- 18 years and over
- People
- 80 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07871214 - Phase 1/2Taking peopleA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Where
- Seoul
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07115043 - No phaseNot yet taking people in South KoreaRobotic Bronchoscopy for Small Lung Nodules Without a Bronchus Sign
- Where
- Daejeon, Goyang-si, Seoul, Ulsan
- Age
- 19 years and over
- People
- 151
- Run by
- Intuitive Surgical
See details and how to joinNCT07862816 - Phase 2Taking peopleA Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
- Where
- Goyang-si, Hwasun-gun, Incheon, Jinju, Seoul, Soeul, Suwon
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT05967689 - Phase 1/2Taking peopleA Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- Where
- Seoul
- Age
- 18 years and over
- People
- 327 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780137 · EU 2024-517926-25-00 - Phase 1/2Taking peopleStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Seoul
- Age
- 18 years to 130 years
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00 - Phase 1/2Taking peoplePhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Seoul
- Age
- 18 years to 130 years
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00 - Phase 2/3Taking peopleA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Busan, Cheongju-si, Seoul
- Age
- 18 years and over
- People
- 854 worldwide
- Run by
- AbbVie
See details and how to joinNCT07005102 - Phase 2/3Taking peopleA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Cheongju-si, Goyang-si, Seoul
- Age
- 18 years and over
- People
- 490 worldwide
- Run by
- AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00